Ad-hoc | 12 August 2015 07:00

Cytos Biotechnology Ltd exclusively licenses its VLP platform for the treatment of Cancer to Checkmate Pharmaceuticals LLC

Cytos Biotechnology AG / Key word(s): Agreement

2015-08-12 / 07:00
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.

Cytos exclusively licenses its VLP platform for the treatment of Cancer to Checkmate Pharmaceuticals LLC

Schlieren (Zurich), Switzerland, August 12, 2015 – Cytos Biotechnology Ltd. (SIX:CYTN) (“Cytos”) announced today that it executed an exclusive license agreement in the field of oncology granting Checkmate Pharmaceuticals LLC, Cambridge, MA, USA (“Checkmate”) exclusive access to Cytos’ clinically validated product candidate CYT003 as well as its VLP platform and to technology related to oligonucleotide synthesis.

Cytos may receive up to USD 90 million in development milestones and may receive up to double-digit royalties on net sales from successfully developed products.

“We are excited about the potential of our immunologically active VLP platform in the field of immune-oncology and believe that Checkmate is well positioned to advance treatment options for patients with cancer”, commented Christian Itin, Chairman and CEO of Cytos.

For further information, please contact:

Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46
harry.welten@cytos.com

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN. Website: www.cytos.com

About Checkmate

Checkmate Pharmaceuticals is a research and development company pursuing a novel approach to specifically activating the innate arm of the immune system to recognize and ultimately destroy tumor cells. The company is leveraging their expertise and the vast body of knowledge in the field of CpG oligonucleotides and is validating an approach that will combine the ability of CpG DNA to activate an anti-tumor T cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. Checkmate’s founder and CEO, Dr. Art Krieg, discovered CpG DNA in 1994 and since then CpG DNAs have been administered to thousands of humans showing potent immune activation and an excellent safety profile. Checkmate is a privately held company headquartered in Cambridge, Mass. Information regarding Checkmate is available on the company’s web site at www.checkmatepharma.com.

Forward Looking Statements
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

End of ad hoc announcement

+++++
Additional features:

Document: http://n.equitystory.com/c/fncls.ssp?u=TAFVQMBTJS
Document title: Cytos Checkmate agreement 150812

2015-08-12 News transmitted by EQS Schweiz AG. www.eqs.com – news archive: http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.

Language:	English
Company:	Cytos Biotechnology AG
	Wagistr. 25
	8952 Schlieren
	Switzerland
Phone:	+41 44 733 4747
Fax:	+41 44 733 4740
E-mail:	info@cytos.com
Internet:	www.cytos.com
ISIN:	CH0011025217, CH0029060735
Valor:	–
Listed:	Regulated Unofficial Market in Berlin, Munich, Stuttgart; Open Market in Frankfurt ; SIX

End of News EQS Group News-Service

385741  2015-08-12